Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

NCT03646370 · clinicaltrials.gov ↗

COMPLETED

Status

110

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection
Metabolic Syndrome
Cardiovascular Diseases
Weight Gain
Renal Function Abnormal
Hyperglycemia

Interventions

DRUG: Tenofovir Alafenamide

Sponsor

Thomas Jefferson University